Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 3, 2016, Pages 439-447

  Weekes, Colin D ^a   Lamberts, Laetitia E ^b   Borad, Mitesh J ^c   Voortman, Johannes ^d   McWilliams, Robert R ^e   Diamond, Jennifer R ^a   De Vries, Elisabeth G E ^b   Verheul, Henk M ^d   Lieu, Christopher H ^a   Kim, George P ^f   Wang, Yulei ^g   Scales, Suzie J ^g   Samineni, Divya ^g   Brunstein, Flavia ^g   Choi, Younjeong ^g   Maslyar, Daniel J ^g   Colon Otero, Gerardo ^f  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MAYO CLINIC   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAYO CLINIC   (United States)

^f MAYO CLINIC   (United States)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CISPLATIN DERIVATIVE; DMOT 4039A; DRUG ANTIBODY; MESOTHELIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PLATINUM;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PERITONITIS; BURNING SENSATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPESTHESIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; ILEUS; IMMUNOHISTOCHEMISTRY; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; INOPERABLE CANCER; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RASH; RECOMMENDED DRUG DOSE; RETREATMENT; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; STOMACH PARESIS; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; RETREATMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84964389814     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0693     Document Type: Article

References (34)

1. Chang K, Pastan I, Willingham MC. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 1992;51:548-54.
2. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
3. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
4. Frierson HF, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-9.
5. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150-8.
6. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
7. Ordoñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51.
8. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelinmediates cell adhesion. J Biol Chem 2004;279:9190-8.
9. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
10. Haglund C. Tumor marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer 1986;54:897-901.
11. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014;74:2907-12.
12. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I. V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
13. Bendell J, Blumenschein G, Zinner R, Hong D, Jones S, Infante J, et al. Firstinhuman phase I dose-escalation study of a novel anti-mesothelin antibody drug conjugate, BAY 94-9343, in patients with advanced solid tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr. 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract nr LB-291.
14. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012;18:858-68.
15. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenesexpressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015;33:1325-33.
16. Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, andmesotheliomamodels. Mol Cancer Ther 2014;13:2630-40.
17. Bai RL, Petit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990;265:17141-9.
18. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
19. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
20. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN 35, a potent anti CD30 antibody drug conjugate. Clin Cancer Res 2010;16:888-97.
21. Gupta N, Solis WA, Fuji RN, Oldendorp A, Pacheco G, Luis E, et al. Nonclinical characterization and tolerability of a surrogate anti-mesothelin-MMAE antibody-drug conjugate. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr. 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr 4502.
22. Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, et al. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents:results of a DLT-TARGETT international survey. Eur J Cancer 2014;50:2050-6.
23. Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 2015;71:444-52.
24. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013;5:201-26
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
26. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012;82:51-77.
27. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Human Path 2004;35:357-66.
28. Liu J, Moore K, Birrer M, Berlin S, Matulonis U, Infante JR, et al. Targeting MUC16 with the antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer: a phase I study of safety and pharmacokinetics. Cancer Res 73:8s, 2013(suppl; abstr LB-290). AACR 2013 Annual Meeting, Apr. 6-10, 2013. Washington DC.
29. Burris HA, Gordon MS, Gerber DE, Spigel DR, Mendelson SD, Schiller JH, et al. A phase I study of DNIB0600A, an antibody-drug conjugate targeting NaPi2b, in patients with non-small cell lung cancer or platinum-resistant ovarian cancer. J Clin Oncol 32:5s, 2014(suppl; abstr 2504).
30. Danila DC, Szmulewitz R, Higano CS, Gilbert H, Kahn R, Wood K, et al. A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 31, 2013(suppl; abstr 5020).
31. Infante JR, Sandhu SK, McNeil CM, Kabbarah O, Li C, Zhong W, et al. A first-in-human phase I study of the safety and pharmacokinetic activity of DEDN6526A, an anti-endothelin B receptor (anti-ETBR) antibody-drug conjugate in patients with metastatic or unresectable melanoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr. 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract nr CT233.
32. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
33. Lindenberg L, Thomas A, Adler S, Mena E, Kurdziel K, Maltzman J, et al. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomographycomputed tomography (SPECT-CT) imaging. Oncotarget 2015;6:4496-504.
34. Lamberts LE, Menke-Van Der Houven Van Oordt CW, Bensch F, Voortman J, Hoekstra OS, Maslyar DJ, et al. PET-imaging with 89Zr-labeled antimesothelin antibody in patients with pancreatic or ovarian cancer. Ann Oncol 25:4s (suppl: abstr iv546-iv563). ESMO 2014 Annual Meeting, Sept. 26-30, Madrid, Spain.